Wuhan Easy Diagnosis Biomedicine Co.,Ltd. Profile Avatar - Palmy Investing

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of in vitro diagnostic reagents and diagnostic equipment in China and internationally. Its products portfolio includes molecular diagnostic products, …

Medical - Devices
CN, Wuhan [HQ]

Ratios

13 Records · Starting from 2011
Margins, Growth Rates In %
Ratio 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Profitability
Gross Margin
62.00 58.80 70.59 71.23 78.95 85.54 81.86 77.10 74.32 78.21 75.02 66.85 54.28
Profit Margin
20.79 19.76 28.22 37.26 37.34 42.34 39.66 34.82 22.92 48.89 49.94 39.97 10.00
Operating Margin
-20.07 17.97 32.04 38.52 43.23 47.59 45.82 38.72 22.93 58.63 60.00 48.24 19.37
EPS Growth
- - 9,185.71 117.95 -82.35 53.33 69.57 7.69 -16.67 -42.86 1,035.00 194.27 170.66 -98.18
Return on Assets (ROA)
12.94 30.10 30.78 35.30 26.57 30.28 25.53 9.95 6.50 32.87 41.36 45.79 1.01
Return on Equity (ROE)
1,180.66 98.49 53.86 43.44 30.85 34.09 27.22 10.44 6.81 42.56 50.67 64.75 1.24
Return on Invested Capital (ROIC)
-1,205.45 80.66 48.28 38.86 29.41 31.88 27.47 10.15 6.26 38.47 51.16 65.39 1.18
Solvency
Equity Ratio
- - - - - - - - - - - - - - - - - - - - - - - - - -
Debt/Assets
- - - - 4.20 - - 3.62 3.41 -0.45 0.87 -0.61 10.29 1.30 2.22 0.67
Debt/Equity
- - - - 7.36 - - 4.20 3.84 -0.48 0.92 -0.64 13.33 1.59 3.13 0.82
Debt/EBITDA
-157.49 -54.91 -61.93 -40.69 -231.26 -125.08 -145.86 -306.96 -266.53 -90.82 -65.79 -38.23 -317.84
Debt/Capitalization
- - - - 6.85 - - 4.03 3.70 -0.48 0.91 -0.65 11.76 1.57 3.04 0.81
Interest Debt per Share CNY
- - 0.02 0.12 - - 0.03 0.04 -0.01 0.03 -0.02 0.71 0.22 0.89 0.26
Debt Growth
- - - - - - -100.00 - - 38.77 -100.00 - - -100.00 - - -68.65 358.99 -75.86
Liquidity
Current Ratio
95.15 110.51 134.63 422.44 655.39 693.39 1,373.88 2,333.47 2,322.75 393.67 549.48 324.82 269.77
Quick Ratio
81.04 60.53 72.76 351.18 605.72 649.85 1,251.75 2,242.63 2,130.02 355.62 497.36 313.89 257.14
Cash Ratio
39.64 33.22 64.13 93.21 568.81 454.87 1,024.25 1,234.82 839.29 216.24 217.97 108.06 99.64
Operating Cash Flow Ratio
- - - - - - 100 200 200 300 200 100 100 200 100 - -
Turnover
Inventory Turnover
206.74 195.30 122.55 206.33 225.00 223.51 201.49 205.18 118.79 177.52 248.43 1,350.89 266.14
Receivables Turnover
102.54 515.96 3,154.97 783.02 1,353.50 967.15 649.85 317.18 341.05 423.98 343.29 375.04 57.28
Payables Turnover
866.59 2,019.24 194.25 475.12 263.37 235.90 733.82 978.19 672.80 675.41 405.62 269.83 50.28
Asset Turnover
62.23 152.37 109.07 94.74 71.17 71.51 64.37 28.58 28.38 67.23 82.81 114.57 10.15
Coverage
Interest Coverage
-479.45 1,529.52 15,753.27 60,820.46 - - - - 1,174,902.98 18,537.87 43,316.10 85,922.95 80,283.50 148,410.93 1,382.94
Asset Coverage
- - - - 1,100 - - 2,400 2,600 - - 10,800 - - 800 6,500 3,400 12,900
Cash Flow Coverage (CFGR)
- - - - 629.61 - - 929.78 875.96 -4,018.34 996.13 -574.06 244.91 2,540.78 1,971.00 798.48
EBITDA Coverage
700 2,100 16,600 70,700 - - - - 1,327,100 23,100 66,700 88,700 82,300 179,700 2,800
Dividend Coverage
-400 -1,600 -13,800 -800 -800 - - - - -200 -200 -7,000 -400 -700 - -
Time Interest Earned (TIE)
- - 100 100 200 200 200 200 100 100 400 500 600 100
Market Prospects
Dividend Yield
0.01 0.25 0.06 0.19 0.28 - - - - 0.79 0.83 0.16 4.01 6.13 11.20
Earnings Yield
0.04 4.14 8.99 1.60 2.48 4.07 4.45 1.83 1.72 11.17 20.03 47.04 1.45
Price/Earnings (P/E)
2,257.3298 24.1518 11.1189 62.6918 40.3576 24.5532 22.4911 54.7930 58.0612 8.9503 4.9930 2.1257 68.8182
Price/Book (P/B)
2,665,131.02 2,378.78 598.84 2,723.15 1,245.00 837.12 612.29 572.19 395.44 380.93 253.02 137.63 85.57
Price/Sales (P/S)
46,931.04 477.13 313.77 2,336.17 1,506.78 1,039.61 892.06 1,908.01 1,330.92 437.60 249.35 84.96 687.93
Price/Cash Flow (P/CF)
-118,376.32 3,278.95 1,293.09 8,196.93 3,190.89 2,490.06 3,168.00 6,270.33 10,722.44 1,166.88 626.10 222.94 1,313.70
End of 002932.SZ's Analysis
CIK: - CUSIP: - ISIN: CNE1000033Q7 LEI: - UEI: -
Secondary Listings
002932.SZ has no secondary listings inside our databases.